Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of its capsid

US9234183B2 · kind B2 · utility

Assignee

• Deutsches Krebsforschungszentrum · DE

Inventors

• Antonio Marchini · Heidelberg, DE
• Nazim El-Andaloussi · Heidelberg, DE
• Jean Rommelaere · Heidelberg, DE
• Barbara Leuchs · Heidelberg, DE
• Xavier Allaume · Montreuil, FR

Key dates

• Filing date: Apr 9, 2013
• Grant date: Jan 12, 2016
• Expiry date: Apr 9, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14332
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy.